Lipid mRNA Vaccine Composition for HPV 6/11 E6-E7 Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines primarily target the L1 protein for prophylaxis, while therapeutic vaccines for HPV infections, particularly those caused by types 6 and 11, focus on nonstructural proteins E6 and E7, but there is a need for improved immunogenicity and efficacy in inducing immune responses against these antigens.
Innovation Solution
Development of lipid particles encapsulating mRNA encoding E6 and E7 antigens of HPV types 6 and 11, utilizing a specific cationic lipid composition to enhance immune response induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HPV vaccines use L1 protein-based VLP antigens for prophylaxis, then protection against HPV infection is achieved, but the ability to treat existing infections and induce strong immune responses against E6 and E7 antigens is insufficient
Solution Approach 1:
The patent combines multiple functions into a single vaccine composition: it includes both L1 VLP antigens for prophylaxis and mRNA encoding E6/E7 antigens for therapeutic effects, creating a unified vaccine that provides both preventive and therapeutic benefits against HPV infections
Solution Approach 2:
The vaccine composition is designed to serve multiple purposes: it prevents HPV infection through L1 VLPs, treats existing infections through E6/E7 mRNA, and can be applied to multiple HPV types (6, 11, 16, 18) making it a universal solution for both prophylaxis and therapy
2Adaptability or versatility
If therapeutic vaccines use E6 and E7 antigens to treat HPV infections, then treatment of existing infections is improved, but immunogenicity and efficacy in inducing strong immune responses remain insufficient
Solution Approach 1:
The patent employs several parameter changes to enhance immunogenicity: uses mRNA instead of traditional protein antigens for better stability and expression, incorporates specific lipid nanoparticle formulations with optimized composition ratios, and modifies the chemical structure of nucleosides in mRNA to improve stability and immune recognition
Solution Approach 2:
The vaccine uses composite lipid nanoparticle materials comprising multiple lipid components (ionizable lipid, phospholipid, cholesterol, PEG-lipid) in specific ratios, combined with modified mRNA, to create a delivery system that enhances both stability and immune response induction
3Reliability
If DNA gene vaccines are used for HPV prevention, then antigen expression is achieved, but the complexity of administration and electroporation requirements reduce ease of use
Solution Approach 1:
The patent replaces the mechanical electroporation system with a biochemical solution: lipid nanoparticle-mediated delivery of mRNA that can be administered through simple injection without requiring complex electroporation equipment or procedures
Solution Approach 2:
The patent changes the physical state and delivery mechanism from DNA (requiring electroporation) to mRNA encapsulated in lipid nanoparticles, which can be delivered through standard injection methods, dramatically simplifying administration while maintaining antigen expression efficacy
Data Source
AI summary
Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and/or treating infection with human papillomavirus type 6 and/or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.[In the formula, R1, R2, p, L1 and L2 are as defined in the specification.]